Medicines missing from pharmacies: for a patient, the problem begins with a simple question at the counter: “Don’t you have my treatment?” But a negative answer can conceal very different situations: a pharmacy temporarily out of stock, a distributor with delayed deliveries, an interruption reported by the manufacturer, a product presentation withdrawn from the market, or an administrative problem. “It is not available at this pharmacy” does not automatically mean “the medicine has disappeared from Romania”.
In Romania, these distinctions have also become an officially documented institutional issue. On 7 October 2026, the Ministry of Health published the results of an audit into medicine availability and announced 16 recommendations to improve monitoring. The audit points to insufficient automated alerts, incomplete reporting and coordination difficulties; it does not claim that every pharmacy reports incorrectly or that all medicines are in shortage. Source: Ministry of Health, audit statement of 7 October 2026.
This InfoBuz guide explains the path of a supply-interruption alert, the difference between official reports and what happens at the pharmacy counter, the roles of the National Agency for Medicines and Medical Devices of Romania (ANMDMR), the Ministry of Health, the European Medicines Agency (EMA) and pharmacies, and the safer steps for someone whose treatment becomes hard to find. This is not presented as a live list of unavailable medicines: the status of a particular product may change between the time of documentation and the time it is read.
Why do medicines disappear from pharmacies? Six situations that should not be confused
| Situation | What it means in practice | What to check |
|---|---|---|
| A local pharmacy stockout | The product is not in stock at the pharmacy asked. | Availability from the distributor, at other pharmacies, and the estimated delivery date. |
| Temporary supply interruption | The marketing authorisation holder reports an interruption for a period. | The ANMDMR document, the exact pharmaceutical form and strength, and the notification date. |
| Permanent supply interruption | A medicine or product presentation is no longer marketed or maintained in distribution. | The official status and whether other authorised medicines exist. |
| A shortage in one distribution chain | The product may be available nationally but not reaching a particular region or certain outlets. | Supply data; it cannot be inferred from one pharmacy alone. |
| A recall or quality issue | There may be restrictions on batches or products for different reasons. | The specific official alert and the authority’s instructions. |
| An administrative or financial blockage | Dispensing or supply may be affected by procedures separate from the medicine’s physical availability. | The precise cause; it should not be confused with a national shortage. |
A “supply interruption” does not always mean stocks have been completely exhausted nationwide. Units may still be available within the supply chain, or authorised alternatives may exist. Conversely, a local problem can disrupt a patient’s treatment even where no official supply-interruption notification has been issued.
What the Ministry of Health audit of 7 October 2026 found
The ministry examined the work of the bodies responsible for medicine availability and stock reporting, including the Electronic Reporting System (S.E.R.), the management of supply interruptions and the procurement procedure for special needs. Its overall conclusion was that the mechanism needs to move from a largely reactive approach to one able to flag risks automatically before patients are affected.
1. The system does not yet automatically flag critical situations sufficiently
The audit found that S.E.R. is not sufficiently automated to identify anomalies in stocks, consumption and reporting in real time. Monitoring still relies heavily on manual analysis, notifications and case-by-case checks. This can delay the identification of shortages. That does not mean the system does not exist, but rather that its alert functions and operational use need improvement.
2. Reporting is not the same as physically verified stock
The ministry refers to the risk that failures to report, incorrect information or differences between physical and declared stock are not detected quickly enough. Any statistic on “available medicines” therefore depends on accurate reporting and data controls. A positive number entered into a system does not automatically mean a patient can be dispensed the product immediately.
3. Information about supply interruptions can be delayed or incomplete
The audit records that public information on supply interruptions is not always complete and up to date. This finding explains why a patient may encounter a situation in which a pharmacy says a product is unavailable while public information does not immediately reflect that case. In itself, it is not evidence that a particular company has concealed a problem.
4. Some special-needs procedures may delay access
The ministry identified monitoring vulnerabilities and delays in procedures involving medicines authorised for special needs, including an explicit reference to lomustine. The audit’s example concerns the risk of delays in authorising the quantities required; it should not automatically be turned into a claim that every product containing that substance was unavailable in all pharmacies on 17 November.
5. Patient and consumption data need to be linked to demand
For certain national programmes, the audit points to the need to base quantities on patient, consumption and reimbursement data. If this information is not synchronised, estimates of need may be insufficient or late. This is a planning issue, separate from whether there is a supplier contract or the product’s physical transport.
6. Controls and inspections need strengthening
The report points to limited inspection capacity compared with the number of outlets monitored, and to a low number of unannounced inspections. Proposed solutions include risk indicators and targeted physical checks, rather than simply increasing the volume of unverified data.
The 16 recommendations: what could change, and what has not yet been demonstrated
The 16 recommendations in the official document are not equivalent to 16 platforms already in operation. The ministry listed among its priorities automated alerts for critical stocks, incorrect reports and failures to report; standardised supply-interruption notifications; clear coordination among institutions; monitoring of special-needs procedures; and stronger enforcement capacity.
| Problem described in the audit | Direction for improvement | What evidence would show progress |
|---|---|---|
| Critical stock identified too late | Automated alerts based on consumption and risk | A public procedure, tested functionality and documented response times. |
| Incomplete public information | Regular updates to supply-interruption records | A list with update dates and a record of changes. |
| Non-compliant reporting | Cross-checks and inspections | A control methodology and aggregate results. |
| Poor estimates for programmes | Linking needs to patient numbers and consumption | Documented procurement methodology and quantities. |
| Special needs managed with difficulty | Clearer deadlines and responsibilities | Data on authorisations and actual availability. |
For public-interest journalism, the central question after such an audit is not only “were recommendations made?” but “how many have been implemented, from what date, and which indicator shows that the patient receives treatment sooner?” At the time of documentation, this article does not treat the list as fully implemented. The Ministry of Health’s official document.
The full path of an alert: from manufacturer to patient
- The marketing authorisation holder identifies a possible or confirmed interruption and submits a notification under the applicable rules.
- ANMDMR receives and assesses information on the product’s status, causes and any alternatives or management measures.
- The Ministry of Health and other involved bodies monitor supply and may use special procedures under the law.
- Distributors and pharmacies report and use data on stocks, orders and delivery capacity.
- The prescriber and pharmacist assess appropriate options within their respective responsibilities, without turning a commercial shortage into an uncontrolled change in treatment.
- The patient should be informed about the product’s specific situation and directed towards a safe solution or medical care when treatment is at risk of interruption.
A single product may have several manufacturers, strengths, pharmaceutical forms and pack sizes. The exact combination under consideration must be distinguished. A notification concerning 5 mg tablets does not establish the unavailability of an injectable solution or of all equivalents containing the same active substance.
Where to check officially whether a medicine has a notified supply interruption
ANMDMR publishes a dedicated section on medicine supply-interruption notifications. The page explains that these are details submitted by marketing authorisation holders about temporary or permanent interruptions in the distribution chain, with records dating from June 2016. Documents may state the trade name, strength, form, active substance, date, type of interruption, expected resumption date and declared reason.
An example from an official ANMDMR table dated 9 September 2026 includes notifications for certain presentations containing donepezil, cefaclor or lacosamide. These are historical entries in the published file, not a live list checked at every pharmacy on 17 November. Some notifications include estimated resumption dates that may change. It would be wrong to infer from an old entry that the active substance can no longer be found in any form.
How to read a notification entry correctly
| Field | Question to ask |
|---|---|
| Trade name | Is this exactly the brand on the prescription, or a different product? |
| INN / active substance | Are there distinct products with the same substance? |
| Strength and form | Does it concern the same dose and route of administration? |
| Temporary or permanent interruption | Is the interruption anticipated, current or permanent? |
| Notification date and expected resumption date | When was the situation documented, and have the dates been revised? |
| Declared reason | Is it manufacturing-related, commercial or another reason? Check the source and context. |
EMA and ESMP: when does the shortage of a product become a European issue?
The European Medicines Agency (EMA) works with national authorities to manage shortages with a major impact and publishes information on critical situations relevant at European level. A European list should not be confused with a real-time inventory of every pharmacy in Romania. Many problems are local, national or tied to specific product presentations, and do not appear in the same way in EMA communications.
The European Shortages Monitoring Platform (ESMP) supports standardised communication about availability and shortages. According to the official summary of an EMA meeting in September 2026, the platform became the main channel for supply-monitoring requests from 15 September, and was scheduled to become the main channel for authorities’ notifications of critical shortages from 1 October. This is a workflow among authorities and relevant stakeholders, not a public search engine for a pharmacy’s stock. Source: EMA, meeting of the shortages working group, September 2026; EMA — ESMP.
Medicines for special needs: an important solution, but not a routine order
When necessary treatment cannot be covered by products available through ordinary arrangements, an authorisation procedure for special needs may be relevant. It involves medical justification, documentation and approvals under the rules; it is not a right to immediate individual import without checks.
In September 2026, the Ministry of Health announced simplified rules: for a new quantity, the procedure can be triggered when the previously authorised stock falls to 30%, compared with 10% previously, with an obligation to act within no more than three working days of reaching that threshold, according to the rules presented by the ministry. These periods describe the administrative process; they are not a promise that every patient will receive the medicine within three days. Ministry of Health — statement on the audit and September changes.
What a patient can do in the first 24 hours when treatment is no longer available
Safety rule: if the medicine is essential for a serious condition, if only one dose remains, or if interruption could cause withdrawal, deterioration or decompensation, contact with the treating doctor or the appropriate medical service should take priority. Do not stop, double or change doses on your own. In the event of severe acute symptoms, seek emergency medical help.
- Write down the exact name, INN, strength, form and quantity on the prescription or package.
- Ask the pharmacist whether the problem is a stockout in that pharmacy, throughout its chain or a notified supply interruption, and whether the possibility of ordering can be checked.
- Check ANMDMR notifications using the precise details; do not treat a notification as proof that all alternatives are absent.
- Contact the prescribing doctor about a suitable option and, where needed, an updated prescription.
- If the treatment is prescribed under a national programme or supplied by a hospital, contact the facility and medical team coordinating the therapy.
- Keep a record of the request date, the response received and the inability to obtain supply, without publishing personal medical information.
- Do not buy from anonymous sources, social-media groups or unauthorised sellers. The risk of counterfeit products, improper storage and unsuitable medicines may be greater than it appears.
Substituting a medicine: the same active substance does not mean the patient can decide alone
Some products with the same active substance, dose, form and route of administration may be appropriate alternatives under their marketing-authorisation and prescribing conditions. Other medicines may require additional care: different delivery devices, relevant excipients, modified-release formulations, non-interchangeable doses, or treatments that require close monitoring.
There are also therapeutic alternatives with a different active substance, but choosing them is a medical decision and may involve dose titration or monitoring. A pharmacy without a specific brand cannot guarantee that every product with the same clinical purpose is equivalent for a particular patient. In particular, avoid independently changing anticonvulsant, hormonal, cardiovascular or oncology treatments.
When the problem is not the medicine, but the prescription and reimbursement
Sometimes a product may physically exist, but dispensing can be delayed by electronic validation, reimbursement conditions, the prescription, or the rules of the programme through which it is provided. These blockages are not the same as a manufacturing or distribution shortage. InfoBuz has separately documented the six points at which a reimbursed prescription can be blocked; this article focuses on the actual availability of products and the path of a supply interruption.
Why a simple map of pharmacies with stock does not solve the problem
A digital inventory can reduce unnecessary trips, but it must answer three questions: how recent the information is, whether the stock is genuinely available, and whether the product can legally be dispensed to the patient under their circumstances. Stock reported yesterday may have since been exhausted. Some products may be reserved for patients, require specific documents, or be supplied through other channels.
In addition, an exhaustive public platform would need to protect commercial and personal data, address reporting errors, and distinguish physical stock from a product that is freely available for sale. The October 2026 audit matters precisely because it called for verification and alerts, not merely the collection of more figures.
Questions institutions should be asked after the 2026 audit
- How many of the 16 recommendations have been implemented, and what public deadlines exist for the remainder?
- Which indicator automatically triggers a critical-stock alert, and who is responsible for checking it?
- How quickly is the supply-interruptions section updated after receipt of a relevant notification?
- What differences have been identified between stocks declared in S.E.R. and those found physically?
- How many special-needs applications have been processed, and over what periods, separately from final delivery?
- How are data on the number of patients in national programmes linked to treatment needs?
- Are there published indicators for the time between the onset of an interruption and access to an appropriate alternative treatment?
These questions form an editorial monitoring plan, not a claim that the Ministry or ANMDMR has taken no action in the meantime. Answers would require current implementation data, separate from the audit’s findings.
Illustrative case study: a medicine with the same INN but different presentations
Hypothetical example, unrelated to a specific product: a person receives a prescription for 30 tablets of 10 mg of a particular medicine. The pharmacy says the prescribed brand is unavailable. The first step is to check whether the interruption concerns the exact brand, the whole 10 mg strength, or only the distributor. The pharmacist and prescriber then assess whether another authorised presentation exists or whether the prescription needs to be legally amended.
Changing to two 5 mg tablets instead of one 10 mg tablet, for example, should not be universally recommended: there may be differences in formulation, conditions of use or product-specific characteristics. The decision in a particular case belongs to competent medical and pharmacy professionals. This example shows why checking the substance, dose and form is more useful than searching for a single trade name.
What the issue looks like at European level
Medicine shortages have varied causes: concentrated manufacturing capacity, quality problems, interruptions in raw materials, seasonal demand, distribution and commercial decisions. A country can face difficulties even where the product is not missing simultaneously in every EU country. EMA and the network of national authorities seek to strengthen the identification of and response to significant shortages, but they cannot promise that all interruptions will disappear.
A better European information chain helps identify risks earlier and coordinate responses. It does not, however, replace factories, procurement planning, inspections, transport or medical decisions in individual cases. That is why a digital-only solution is insufficient.
Frequently asked questions: medicines missing from pharmacies
If a pharmacy does not have a medicine, does that mean it is unavailable throughout Romania?
No. The situation may be local, related to a supplier or to a particular package. A national shortage or official supply interruption requires further checks.
Where can I find the list of medicines with notified supply interruptions?
On the ANMDMR page on supply-interruption notifications. Check the document date and identify the exact name, strength and form; the list is not a medicine-reservation system.
Can a product be notified as unavailable but still be found in a pharmacy?
Yes. The notification may concern future distribution or a particular period, while some outlets may still have existing stock. The specific situation must be checked when the medicine is requested.
Can I take another medicine with the same active substance?
Pharmaceutical alternatives sometimes exist, but it is not safe to assume interchangeability for all medicines. The pharmacist and doctor must check the product, form, dose and prescribing conditions.
What should I do if I need the medicine today and cannot find it?
Contact the prescriber or medical service overseeing your treatment without delay, especially for medicines whose interruption may be dangerous. In a medical emergency, seek urgent assessment; do not improvise doses or products.
Can all missing medicines be imported through the special-needs procedure?
Not automatically. There are authorisation and justification requirements, and the procedure is not a direct patient order without assessment and documentation.
Does reporting to EMA mean that every pharmacy can be checked in real time?
No. ESMP is a European coordination and reporting tool, not a universal interface to stock at every pharmacy counter.
Conclusion: patients need treatment, not only a statistic
A medicine can “disappear” from a patient’s perspective before the problem becomes visible in a national register. The audit published in October 2026 shows why Romania needs better reporting, automated alerts, checks and clear responsibilities. But real progress will be visible only if an alert leads to action before a patient has to interrupt treatment.
The test for 2027: how long passes between the first signal of a shortage and identifying and accessing a safe solution for the person affected? The number of notifications and institutional recommendations matters; however, the time to a concrete resolution is the indicator that matters most to patients.
Primary sources, methodology and clarifications
- Ministry of Health — audit of medicine availability, 7 October 2026: findings and 16 recommendations.
- Ministry of Health — announcement launching the audit, 26 August 2026: institutional context.
- ANMDMR — supply-interruption notifications: official page with situations reported by marketing authorisation holders.
- ANMDMR — notification file of 9 September 2026: dated examples of supply interruptions.
- EMA — Medicine shortages: shortage management and the European context.
- EMA — European Shortages Monitoring Platform: the European collection and monitoring mechanism.
- EMA — shortages group report, September 2026: timetable for ESMP use.
Editorial note, 17 November 2026: this article is an analysis of the supply mechanism, not individual medical advice or a real-time list of stocks. Historical examples from registers do not automatically establish a medicine’s availability on the date of reading. The representative image is an AI illustration, not a photograph of an actual shortage case.






Discuția cititorilor
Ai o opinie sau o întrebare despre acest articol? Spune-ne ce crezi.
Fii primul care deschide discuția.
Te rugăm să păstrezi un limbaj civilizat și să discuți la subiect. Comentariile spam sunt filtrate automat.